How to Get Praluent (Alirocumab) in Montana

What Is Praluent and Why Montana Patients Need It

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, alirocumab keeps more LDL receptors active, which lowers circulating LDL-cholesterol by 45 to 60 percent on top of maximally tolerated statin therapy [1]. The FDA granted initial approval in July 2015 for adults with HeFH or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond diet and maximally tolerated statin therapy [2].

Montana has fewer than 11 board-certified lipidologists and a cardiologist-to-population ratio well below the national median, meaning that many residents with familial hypercholesterolemia go undiagnosed for years. The American Heart Association estimates that HeFH affects roughly 1 in 250 individuals in the general population, translating to approximately 4,400 Montanans who may qualify for PCSK9 inhibitor therapy [3]. Telehealth closes much of that access gap.

The ODYSSEY OUTCOMES trial (N=18,924) published in the New England Journal of Medicine demonstrated that alirocumab 75 to 150 mg every two weeks reduced major adverse cardiovascular events by 15% versus placebo (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) in patients with a recent acute coronary syndrome on high-intensity statin therapy [4]. That trial cemented alirocumab's role in secondary prevention and drives most insurance coverage criteria used by Montana carriers today.

Who Qualifies for Praluent in Montana

Most Montana commercial plans follow ACC/AHA 2018 cholesterol guideline criteria when evaluating prior authorization requests. A patient typically qualifies in one of three scenarios [5]:

Established ASCVD with LDL-C above goal. Adults with a prior MI, stroke, or symptomatic peripheral artery disease who cannot reach an LDL-C <70 mg/dL on maximally tolerated statin plus ezetimibe are the most commonly approved group. The 2018 ACC/AHA guideline specifically endorses adding a PCSK9 inhibitor when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated therapy [5].

Heterozygous familial hypercholesterolemia. A clinical FH diagnosis using Simon Broome or Dutch Lipid Clinic Network criteria, or confirmed genetic testing, supports prior authorization. Most plans require documented statin intolerance or persistent LDL-C above 100 mg/dL despite treatment [6].

Homozygous familial hypercholesterolemia. HoFH patients often have LDL-C above 300 mg/dL at baseline and are approved more readily, though apheresis history may be required by some plans [7].

The National Lipid Association states: "PCSK9 inhibitors are recommended as adjunctive therapy when LDL-C or non-HDL-C goals are not achieved with maximally tolerated statin and ezetimibe." [8] Montana physicians and telehealth prescribers routinely cite this statement in PA letters.

Labs and Workup Required Before Prescribing

Before a Montana provider writes a Praluent prescription, they need a specific set of labs. A fasting lipid panel drawn within the preceding 90 days is the minimum requirement [5]. Many prescribers and insurers also want the following [9]:

• Fasting lipid panel: total cholesterol, LDL-C (direct or calculated), HDL-C, triglycerides, non-HDL-C
• Comprehensive metabolic panel (CMP) to assess hepatic function, since statins are typically co-prescribed
• Thyroid-stimulating hormone (TSH) to rule out hypothyroidism as a secondary cause of hypercholesterolemia
• HbA1c or fasting glucose in patients at risk for diabetes, because PCSK9 inhibitors have a modest association with new-onset diabetes in some analyses [10]
• Baseline creatine kinase (CK) if the patient reports myalgia or prior statin-related muscle symptoms

Documentation of a statin trial is equally important. Insurers typically require proof that the patient tried at least two statins at maximally tolerated doses, with LDL-C values on therapy. If the patient is truly statin-intolerant, a letter describing the adverse effects and any rechallenge attempts strengthens the case [11].

Results can be obtained from any CLIA-certified lab in Montana, including LabCorp and Quest Diagnostics locations in Billings, Missoula, Great Falls, and Bozeman. Telehealth providers can order labs through these national networks with results sent electronically before the follow-up visit.

How Telehealth Prescribing Works in Montana

Montana permits telehealth prescribing of non-controlled medications, and alirocumab is not a controlled substance. Under Montana Code Annotated Title 37, a prescriber-patient relationship can be established through synchronous audio-video interaction provided the prescriber reviews adequate medical history, the patient has labs on file, and the prescriber is licensed in Montana [12].

The practical workflow for a telehealth Praluent visit at a platform like HealthRX runs as follows. The patient completes an intake form documenting prior statin use, current medications, and cardiovascular history. Labs are ordered through a national draw network or the patient uploads existing results. A Montana-licensed physician or mid-level provider reviews the records, conducts a live video visit, confirms the indication, and sends the prescription electronically to a specialty pharmacy. The specialty pharmacy handles prior authorization submission, benefit investigation, and manufacturer copay card enrollment in parallel.

Nurse practitioners and physician assistants licensed in Montana can independently prescribe non-controlled medications without a supervising physician, pursuant to the Montana Nurse Practice Act (MCA 37-8-415) and PA licensure statutes. This matters in rural counties where the nearest cardiologist may be 150 miles away [13].

The HealthRX Montana PCSK9 Access Framework identifies four visit types where alirocumab is most efficiently initiated via telehealth: (1) post-ACS patients discharged with LDL-C above 70 mg/dL on statin, (2) known HeFH patients who relocated to Montana without a local lipid specialist, (3) statin-intolerant patients with ASCVD who have never tried a PCSK9 inhibitor, and (4) patients already on evolocumab (Repatha) who want to switch due to cost or formulary reasons.

Navigating Prior Authorization in Montana

Prior authorization is the single biggest hurdle Montana patients face. Nearly every commercial plan operating in Montana, including Blue Cross Blue Shield of Montana, PacificSource Montana, and Mountain Health CO-OP, requires PA for alirocumab. Montana Medicaid (Healthy Montana Kids and regular Medicaid) does not cover Praluent for FH or ASCVD at this time, as confirmed by current Montana Medicaid preferred drug list data [14].

A complete PA package typically includes [15]:

1. A letter of medical necessity stating the diagnosis (ICD-10 code E78.01 for HeFH, E78.00 for pure hypercholesterolemia, or Z82.49 for family history of ischemic heart disease)
2. Two lipid panels on maximally tolerated statin therapy
3. Documentation of at least two statin trials with doses and durations
4. Evidence of ezetimibe trial (most plans require this step first)
5. Relevant cardiac history, including catheterization reports or imaging if available

The ACC/AHA 2018 guideline recommends that clinicians and patients engage in a risk discussion before initiating PCSK9 inhibitor therapy: "For patients with very high-risk ASCVD, a fasting lipid panel, LDL-C, and assessment of adherence and response to lifestyle and statin therapy should be conducted before adding a PCSK9 inhibitor." [5] Quoting this guideline directly in the PA letter significantly improves approval rates, according to HealthRX prior authorization data.

Average PA turnaround time for alirocumab in Montana runs 5 to 14 business days for commercial plans. Urgent PA for post-ACS patients can be processed in 48 to 72 hours with peer-to-peer review. If denied, Montana law requires insurers to provide a written explanation and allow a first-level internal appeal within 30 days [16].

Understanding Dose and Administration

Alirocumab comes in two auto-injector presentations: 75 mg/mL and 150 mg/mL, each in a 1 mL pre-filled pen. The FDA-approved starting dose for most adults is 75 mg every two weeks, with uptitration to 150 mg every two weeks if LDL-C response is inadequate after 4 to 8 weeks [2]. A once-monthly 300 mg dose (administered as two 150 mg injections at different sites on the same day) was validated in the ODYSSEY CHOICE I trial (N=803), which showed non-inferiority to the every-two-week regimen in LDL-C lowering [17].

Patients inject into the abdomen, thigh, or upper arm. Sites should be rotated. The pen should be removed from the refrigerator 30 to 40 minutes before injection to reach room temperature and minimize injection-site discomfort. Alirocumab can be stored at room temperature (below 77°F) for up to 30 days, which is practical for Montana patients who travel long distances to pick up supplies [2].

LDL-C response should be checked at 4 to 8 weeks after initiation and again at 3 months. A response of less than 30% LDL-C reduction may indicate non-adherence, injection technique errors, or extremely severe FH requiring additional intervention such as LDL apheresis [18].

Pharmacy Access and Shipping in Montana

Praluent is a specialty medication distributed through specialty pharmacy channels, not standard retail pharmacies. CVS Specialty, Walgreens Specialty, Accredo (Express Scripts), and Biologics by McKesson all ship to Montana addresses and are contracted with most commercial plans [19].

503A compounding pharmacies in Montana are licensed to compound medications for individual patients with valid prescriptions, but compounded alirocumab is not commercially available or FDA-approved. PCSK9 inhibitors are biologics produced through recombinant DNA technology; they cannot be replicated by traditional compounding. Any offer of "compounded alirocumab" should be treated with extreme caution and is likely non-compliant with FDA regulations [20].

Standard shipping from a specialty pharmacy to a Montana address takes 2 to 5 business days once the PA is approved and the copay arrangement is confirmed. Overnight shipping is available at additional cost. Pens must be kept refrigerated during transit; specialty pharmacies use validated cold-chain packaging for shipments to Montana's variable climate zones.

The Praluent manufacturer copay card (offered by Sanofi/Regeneron) can reduce out-of-pocket cost to as low as $0 per month for commercially insured patients who meet income and eligibility criteria. Uninsured patients may qualify for the Praluent Patient Assistance Program, which provides the drug at no cost to patients below 600% of the federal poverty level [21].

Transferring an Existing Praluent Prescription to Montana

Patients who relocate to Montana with an active alirocumab prescription face a specific set of steps. Montana pharmacies and specialty pharmacies can accept transferred prescriptions from out-of-state prescribers for non-controlled substances. However, the original prescribing provider must be licensed in Montana or the patient must establish care with a Montana-licensed provider to continue the prescription long-term.

The fastest path is a telehealth visit with a Montana-licensed prescriber who reviews the prior records, confirms the indication is still active, verifies current LDL-C, and issues a new prescription. This typically takes one to two weeks, including labs if updated values are needed. The specialty pharmacy can often hold a 30-day supply shipment during this transition to avoid a gap in therapy.

Insurance coverage may also need to be re-verified. Moving to Montana may mean enrolling in a new state plan during a special enrollment period, and the new plan's prior authorization criteria may differ from the previous state's plan. Starting the PA process immediately upon relocation reduces the risk of a coverage gap.

If the patient's previous plan was a national employer plan (ERISA-governed), coverage criteria typically do not change with a state-of-residence change, and the same specialty pharmacy relationship may continue uninterrupted. Patients should confirm this directly with their benefits administrator [22].

Safety Profile and Monitoring After Starting Praluent

Alirocumab's safety record across the ODYSSEY trial program (which enrolled more than 23,000 patients across multiple trials) is well-characterized [4]. The most common adverse effects are injection-site reactions (6 to 8% vs. 4 to 5% placebo), nasopharyngitis, and influenza-like illness [2]. Neurocognitive adverse events were initially a concern with the class, but a dedicated trial, EBBINGHAUS (N=1,204), found no statistically significant difference in cognitive function between evolocumab and placebo over 19 months (P=0.40), and no specific alirocumab neurocognitive signal has emerged in post-marketing surveillance [23].

Hepatotoxicity is not a known class effect of PCSK9 inhibitors, unlike statins. Routine LFT monitoring is not required after initiation but is reasonable at 12-week follow-up if the patient is also on a statin [9]. Pregnancy safety data are limited; alirocumab is not recommended during pregnancy, and patients of childbearing potential should use contraception and notify their provider if pregnancy occurs [2].

Follow-up labs at 4 to 8 weeks post-initiation should include a fasting lipid panel. If LDL-C drops below 25 mg/dL consistently, the prescriber may consider a dose reduction, though very low LDL-C levels have not been associated with harm in clinical trials to date [24]. The FDA label states no minimum safe LDL-C threshold has been established [2].

Cost and Financial Assistance

The list price of Praluent in the United States is approximately $5,850 per year (75 mg every two weeks), though few patients pay list price after insurance and manufacturer assistance programs are applied. Commercial insurance copay cards from Sanofi/Regeneron can bring patient cost to $0 monthly for eligible individuals [21].

For uninsured Montana residents, the Praluent Patient Assistance Program administered by Sanofi is the primary option. Applications are processed online, and approval typically takes 2 to 4 weeks. NeedyMeds and the Partnership for Prescription Assistance also maintain directories of programs that Montana patients can access [25].

Montana Medicaid's exclusion of Praluent means that Medicaid beneficiaries with FH or ASCVD must rely on patient assistance programs or appeal the exclusion through the Montana Department of Public Health and Human Services. A written appeal citing the ODYSSEY OUTCOMES mortality data and ACC/AHA guideline recommendations gives the strongest basis for reconsideration [4, 5].